Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802570 | 0.83 | AKR1B1 (0.39) | AKR1B1ALDH1A1 | |
| SCHEMBL21957680 | 0.76 | CHRM2 (0.43) | — | |
| SCHEMBL19682334 | 0.72 | CHRM2 (0.42) | — | |
| SCHEMBL19682935 | 0.71 | CHRM2 (0.49) | — | |
| SCHEMBL20872788 | 0.68 | CHRM2 (0.51) | — | |
| SCHEMBL19682780 | 0.68 | CHRM2 (0.41) | — | |
| SCHEMBL22492165 | 0.64 | CHRM2 (0.44) | — | |
| SCHEMBL19682931 | 0.61 | CHRM2 (0.46) | — | |
| SCHEMBL20872572 | 0.61 | NOTUM (0.40) | ALDH1A1 | |
| SCHEMBL19682914 | 0.61 | CHRM2 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| US-12344588-B2 | Sulfonamide compounds and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-01 | — | — | US | disclosed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| EP-3717462-A1 | SULFONAMIDE COMPOUNDS AND USE THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | AKR1B1 3303/4885ALDH1A1 2960/4885 |
| US-12344588-B2 | Sulfonamide compounds and use thereof | STS, SULT2A1, TPST2 | AKR1B1 3303/4885ALDH1A1 2960/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | AKR1B1 171/4885ALDH1A1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.